Tesamorelin vs CJC-1295: Research Comparison | Peptide Intel Hub

Tesamorelin is a stabilised 44-amino-acid analogue of native human GHRH with a trans-3-hexenoyl modification at the N-terminus that protects against DPP-4 degradation while preserving the full 44-residue sequence.

CJC-1295 is a truncated 30-residue GHRH analogue with four amino-acid substitutions that increase resistance to enzymatic degradation. The 'with DAC' variant adds a drug-affinity-complex (maleimidopropionic acid) modification that promotes covalent albumin binding and substantially extends the half-life; the 'no DAC' variant is the unmodified short analogue.

Both compounds act as agonists at the GHRH receptor, driving pulsatile growth-hormone release through the native pituitary axis. The downstream IGF-1 response in research models follows the GH pulse.

Tesamorelin's full 44-residue sequence preserves the receptor-binding geometry of native GHRH more closely than the truncated CJC-1295 sequence; CJC-1295 with DAC trades some receptor-binding fidelity for a substantially longer pharmacokinetic profile.

Tesamorelin has an extended pharmacokinetic profile relative to native GHRH thanks to the trans-3-hexenoyl modification — daily research cadence is typical. CJC-1295 no DAC sits in a similar daily-cadence window.

CJC-1295 with DAC has a substantially longer half-life — multi-day, suitable for weekly research cadence — driven by covalent albumin binding through the DAC modification. The trade-off is a less pulsatile GH-release profile and a sustained rather than pulsatile IGF-1 signal in research models.

Tesamorelin is widely used in metabolic, lipodystrophy and body-composition research models, often in the same protocol arms as the published clinical literature. It remains the GHRH-axis reference compound for full-sequence work.

CJC-1295 no DAC is used when a short-acting, pulsatile GHRH-axis research compound is needed. CJC-1295 with DAC is used when a sustained, multi-day GHRH-axis profile is needed — typically paired with ipamorelin in growth-hormone secretagogue research panels.

Both Tesamorelin and CJC-1295 should only be sourced from suppliers that use independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds should be published by the supplier so a researcher can audit the analytical detail. The /trust/how-to-read-a-coa reference walks through every field on a modern COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration. Light exposure should be minimised for both compounds during reconstitution and storage.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both Tesamorelin and CJC-1295 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose tesamorelin when the protocol requires the full 44-residue GHRH-axis activation with a daily research cadence and when leveraging the published clinical literature is part of the project design. Researchers choose CJC-1295 no DAC when a short-acting pulsatile profile is needed, and CJC-1295 with DAC when a sustained multi-day profile (often paired with ipamorelin) is the experimental requirement.

For multi-compound comparator studies, reputable suppliers can often reserve matched-batch inventory of both Tesamorelin and CJC-1295 against a project timeline so the experimental panel is sourced under a single analytical specification window.

Both Tesamorelin and CJC-1295 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on Peptide Intel Hub exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.